Artelo Biosciences logo
Artelo Biosciences
ARTL | NASDAQ
Chart Builder DCF Calculator
$1.70
-$0.37 (-17.87%)
At close: Nov 16, 2026, 4:00 PM ET
$1.69
-$0.01 (-0.64%)
After-hours: Nov 16, 2026, 7:58 PM ET

Artelo Biosciences Company Profile

Company profile explained

Company Profile

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

Key Executives

Name Position
Gregory D. Gorgas President, Chief Executive Officer, Secretary & Director
Mark E. Spring Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer
Andrew Yates Senior Vice President & Chief Scientific Officer
Jason H. Baybutt Senior Vice President of Finance
Steven D. Reich Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 09, 2026 8-K Current Report
Aug 27, 2026 8-K Current Report
Aug 20, 2026 10-Q/A [Amend] Quarterly Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 10-Q Quarterly Report
Jul 21, 2026 4 Filing
Jul 21, 2026 4 Filing
Jul 21, 2026 4 Filing
Jul 21, 2026 4 Filing
View All SEC Filings ➞
Artelo Biosciences
Artelo Biosciences logo
Country United States
IPO Date Jun 21, 2019
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Gregory D. Gorgas

Contact Details

505 Lomas Santa Fe Solana Beach, California 92075 United States

Stock Details

Ticker Symbol ARTL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001621221
CUSIP Number 04301G805
ISIN Number US04301G8050
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.